Long Term Outcomes of the Transcatheter Pulmonary Valve Melody

Original title: Clinical and Hemodynamic Outcomes Up to 7 Years After Transcatheter Pulmonary Valve Replacement in the US Melody Valve Investigational Device Exemption Trial. Reference: Circulation. 2015 May 5. [Epub ahead of print].

Published studies on transcatheter pulmonary valve replacement with the Melody valve have shown good short term outcomes but there is no information of long term outcomes.

The US Investigational Device Exemption trial prospectively enrolled 171 pediatric and adult patients (median 19 years) with right ventricular outflow tract conduit obstruction and/or regurgitation. 148 of these patients received a Melody TPV, were discharged and followed up annually according to a standard protocol. 

At 4.5 year median follow up (0.4-7 years), 32 patients underwent intervention: 27 for valve stenosis, 3 for endocarditis and 2 for valve dysfunction. 

At 5 years, survival rate free from reintervention was 76±4%.  In 113 patients that reached 4.5 years free from reintervention, the right ventricular outflow tract gradient saw no change compared to the one obtained immediately after valve release and almost all patients were a functional class I – II.

Conclusion

The transcatheter pulmonary valve replacement with the Melody valve showed good hemodynamic and clinical outcomes at 7 year follow up. 

Editorial Comment

The most frequent cause of valve dysfunction was stenosis associated in most cases (22 out of 27) with stent fracture. This fracture became less frequent when pre-stenting became more widely adopted. 

SOLACI

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...